治疗慢性鼻窦炎伴鼻息肉的国内药物临床研究现状

doi:10.6040/j.issn.1671-7554.0.2024.0111

摘要/Abstract

摘要： 慢性鼻窦炎(chronic rhinosinusitis, CRS)临床表现为长期鼻塞、流涕、嗅觉减退,严重影响患者的生活质量。CRS发病具有高度异质性,伴有鼻息肉的“表型”为慢性鼻窦炎伴鼻息肉(chronic rhinosinusitis with nasal polyps, CRSwNP)。针对传统治疗药物疗效有限和CRSwNP患者术后复发的问题,已开展多种靶向内在型标志物的生物制品临床试验。近年来,我国治疗CRSwNP的药物临床研究快速发展,国内企业自主研发品种不断涌现,为CRSwNP患者尤其是重度难治性CRSwNP患者带来了新的选择。通过探讨国内治疗CRSwNP药物临床研究现状和发展趋势,为我国CRSwNP治疗药物的研发提供信息参考。

关键词: 慢性鼻窦炎, 鼻息肉, 靶向药物, 临床试验

Abstract: The clinical manifestations of chronic rhinosinusitis(CRS)are chronic nasal congestion, runny nose, and loss of sense of smell, which seriously affect the patients quality of life. The pathogenesis of CRS is highly heterogeneous, and the phenotype associated with nasal polyps is chronic rhinosinusitis with nasal polyps(CRSwNP). Clinical trials of various biological agents targeting intrinsic biomarkers have been conducted to address the limited efficacy of traditional treatment drugs and postoperative recurrence in patients with CRSwNP. In recent years, clinical research for the treatment of CRSwNP in China has flourished, and self-developed varieties of domestic enterprises continue to emerge, bringing new choices for CRSwNP patients, especially those with severe and refractory CRSwNP. By summarizing the current status and development trends of clinical research for the treatment of CRSwNP in China, this study aims to provide information and reference for the research and development of drugs for treating CRSwNP.

Key words: Chronic rhinosinusitis, Nasal polyps, Targeted drug, Clinical trials

中图分类号:

曹原,张剑桥,孟祥伟,刘文,庞晓明. 治疗慢性鼻窦炎伴鼻息肉的国内药物临床研究现状[J]. 山东大学学报 (医学版), 2024, 62(12): 38-42.

CAO Yuan, ZHANG Jianqiao, MENG Xiangwei, LIU Wen, PANG Xiaoming. Current status of drug clinical research for the treatment of chronic rhinosinusitis with nasal polyps in China[J]. Journal of Shandong University (Health Sciences), 2024, 62(12): 38-42.

参考文献

[1] 姚爽, 娄鸿飞. 慢性鼻窦炎的内在型研究进展及精准医疗[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 20-29. YAO Shuang, LOU Hongfei. Advances in endotypes and precision medicine in chronic rhinosinusitis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 20-29.
[2] 白瑜蓉, 张雅娜. 2型生物制剂和亚洲慢性鼻窦炎[J]. 中山大学学报(医学科学版), 2022, 43(5): 720-729. BAI Yurong, ZHANG Yana. Type 2 biologics and Asian chronic rhinosinusitis[J]. Journal of Sun Yat-sen University(Medical Sciences), 2022, 43(5): 720-729.
[3] 史剑波, 孙悦奇, 许庚. 基于内在型的慢性鼻窦炎手术治疗策略[J]. 中华耳鼻咽喉头颈外科杂志, 2022, 57(2): 130-135. SHI Jianbo, SUN Yueqi, XU Geng. Endotype-based surgical treatment of chronic rhinosinusitis[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2022, 57(2): 130-135.
[4] Klingler AI, Stevens WW, Tan BK, et al. Mechanisms and biomarkers of inflammatory endotypes in chronic rhinosinusitis without nasal polyps[J]. J Allergy Clin Immunol, 2021, 147(4): 1306-1317.
[5] Kato A, Peters AT, Stevens WW, et al. Endotypes of chronic rhinosinusitis: relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches[J]. Allergy, 2022, 77(3): 812-826.
[6] 中华医学会变态反应学分会. 2型炎症性疾病机制及靶向治疗专家共识[J]. 中华医学杂志, 2022,102(42):3349-3373. Chinese Society of Allergy, Chinese Medical Association. Expert Consensus on Mechanisms and Targeted Therapy of Type 2 Inflammatory Diseases[J]. Natl Med J China, 2022, 102(42): 3349-3373.
[7] 张雅娜, 吴庆武, 黄雪琨, 等. 基于人工智能的慢性鼻窦炎内在型诊断助力精准医学[J]. 中华耳鼻咽喉头颈外科杂志, 2022, 57(2): 222-226. ZHANG Yana, WU Qingwu, HUANG Xuekun, et al. Chronic rhinosinusitis endotype diagnosis based on artificial intelligence facilitates precision medicine[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2022, 57(2): 222-226.
[8] DeConde AS, Soler ZM. Chronic rhinosinusitis: Epidemiology and burden of disease[J]. Am J Rhinol Allergy. 2016, 30(2): 134-139.
[9] Lou HF, Meng YF, Piao YS, et al. Predictive significance of tissue eosinophilia for nasal polyp recurrence in the Chinese population[J]. Am J Rhinol Allergy, 2015, 29(5): 350-356.
[10] Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis[J]. J Allergy Clin Immunol, 2015, 136(6): 1431-1440.
[11] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科学组.中国慢性鼻窦炎诊断和治疗指南(2018)[J]. 中华耳鼻咽喉头颈外科杂志, 2019, 54(2): 81-100. Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery, Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of chronic rhinosinusitis(2018)[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2019, 54(2): 81-100.
[12] Wen W, Liu W, Zhang L, et al. Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy[J]. J Allergy Clin Immunol, 2012, 129(6): 1522-1528.
[13] Wallwork B, Coman W, Mackay-Sim A, et al. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis[J]. Laryn-goscope, 2006, 116(2): 189-193.
[14] Zeng M, Wang H, Liao B, et al. Clinical and biological markers predict the efficacy of glucocorticoid and macrolide-based postoperative therapy in patients with chronic rhinosinusitis[J]. Am J Rhinol Allergy, 2021, 35(5): 596-606.
[15] Bachert C, Gevaert P, Holtappels G, et al. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation[J]. J Allergy Clin Immunol, 2001, 107(4): 607-614.
[16] Le Floch A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation[J]. Allergy, 2020, 75(5): 1188-1204.
[17] Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps(LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials[J]. Lancet, 2019, 394(10209): 1638-1650.
[18] Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps[J]. J Allergy Clin Immunol, 2006, 118(5): 1133-1141.
[19] Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps(SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Respir Med, 2021, 9(10): 1141-1153.
[20] Liu T, Yu X, Liang Y, et al. Thymic stromal lymphopoietin promotes nasal polypogenesis by regulating CD4⁺ T cell responses[J]. Allergy, 2018, 73(5): 1023-1033.
[21] Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma[J]. N Engl J Med, 2021, 384(19): 1800-1809.
[22] 中华医学会呼吸病学分会哮喘学组. 奥马珠单抗治疗过敏性哮喘的中国专家共识(2021版)[J].中华结核和呼吸杂志, 2022, 45(4): 341-354. Chinese Thoracic Society Asthma Group. Chinese expert consensus on the use of omalizumab in allergic asthma(2021 version)[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2022, 45(4): 341-354.
[23] 申珅, 娄鸿飞, 闫冰, 等. 抗IgE单克隆抗体治疗合并哮喘的复发性慢性鼻窦炎伴鼻息肉的短期疗效研究[J]. 中华耳鼻咽喉头颈外科杂志, 2021,56(10): 1035-1041. SHEN Shen, LOU Hongfei, YAN Bing, et al. Short-term efficacy of anti-IgE monoclonal antibody in patients with recurrent chronic rhinosinusitis with nasal polyps combined with asthma[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2021,56(10): 1035-1041.
[24] Zheng M, Sima YT, Liu CY, et al. Clinical effectiveness and potential predictability of omalizumab in patients with difficult-to-treat chronic rhinosinusitis with nasal polyps and asthma based on the noninvasive markers-A real-life prospective study[J]. World Allergy Organ J, 2022, 15(10): 100702.
[25] Steehler AJ, Vuncannon JR, Wise SK, et al. Central compartment atopic disease: outcomes compared with other subtypes of chronic rhinosinusitis with nasal polyps[J]. Int Forum Allergy Rhinol, 2021, 11(11): 1549-1556.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed